豬鏈球菌(Streptococcus suis, S. suis)主要引起豬的腦膜炎、敗血症，亦為一種人畜共通傳染病。溶血素(suilysin , Sly)是豬鏈球菌關鍵的毒力因子，會與細胞膜上膽固醇結合進而穿孔，再與其他毒力因子合作造成細胞裂解。研究指出，Sly在豬鏈球菌感染與炎症反應中起重要作用，低濃度Sly會刺激細胞激素分泌使嗜中性球和巨噬細胞，自然殺手細胞和細胞毒性T細胞的活化，引發TH1和TH2免疫反應，可以作為一種候選佐劑。本研究已成功使用原核系統表現重組Sly蛋白，確認蛋白質產物大小及抗原性，並完成Sly重組蛋白純化，搭配本實驗室已構築重組巴氏桿菌抗原製成疫苗免疫仔豬，利用流式細胞儀測定CD4+與CD8+ T細胞數量、酵素連結免疫分析抗體、Real-time PCR測定細胞激素表現量及攻毒試驗，藉此評估佐劑效力。

Streptococcus suis (S. suis) causes meningitis septicemia of swine and it is also a zoonotic disease. Suilysin (Sly) is an essential virulence factors of streptococcus suis and creates transmembrane pores in cholesterol-containing membranes thereby causing cell lysis. Sly plays an important role in S. suis infection and inflammation. Low concentration sly can stimulate cytokine secretion, neutrophil, macrophage, natural killer cell and cytotoxic T cell, causing TH1 and TH2 immune response as a candidate adjuvant. We have constructed a gene fragment that removes toxicity and confirmed the size and antigenicity of the recombinant sly protein product. The sly recombinant protein has been purified successfully, combined with constructed rPMT-NC, and prepared as vaccine. Piglet were then immunized with the vaccine. We will evaluate adjuvant efficacy by ELISA analysis, and cytokine production by Real-time PCR. We will measure CD4+ and CD8+ T cells percentages by flow cytometry. We will perform challenge tests to evaluate vaccine protection rate.

參考文獻
1. Ahn KK, Lee YH, Ha Y, Kim D, Chae S, Kim CH, et al. Detection by in-situ hybridization of Pasteurella multocida toxin (toxA) gene in the lungs of naturally infected pigs. J Comp Pathol. 2008;139:51-3.
2. Akira, S.; Takeda, K.Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4, 499–511.
3. Arends, J. P. and H. C. Zanen. Meningitis caused by Streptococcus suis in humans. Rev. Infect. Dis. 10: 131-137, 1988
4. Baums CG, Kock C, Beineke A,Bennecke K,Goethe R,Schroder C,Waldmann K H,Valentin-Weigand P, Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9. Clinical and Vaccine Immunology 2009,16:200-208.
5. Benga L, Fulde M, Neis C, Goethe R, and Valentin-Weigand P. Polysaccharide capsule and suilysin contribute to extracellular survival of Streptococcus suis co-cultivated with primary porcine phagocytes. Veterinary microbiology 132: 211-219, 2008.
6. Bethe A, Wieler LH, Selbitz HJ, Ewers C. Genetic diversity of porcine Pasteurella multocide strains form the respiratory tract of healthy and diseased swine. Vet Microbiol. 2009;139:97-105.
7. Bi L, Pian Y, Chen S, Ren Z, Liu P, Lv Q, et al. Toll-like receptor 4 confers inflammatory response to Suilysin. Front Microbiol. 2015;6:644.
8. Cambier JC, Pleiman CM, and Clark MR. Signal transduction by the B cell antigen receptor and its coreceptors. Annual review of immunology 12: 457-486, 1994.
9. Chabot-Roy G, Willson P, Segura M, Lacouture S, and Gottschalk M. Phagocytosis and killing of Streptococcus suis by porcine neutrophils. Microbial pathogenesis 41: 21-32, 2006.
10. Charland N, Kobisch M, Martineau-Doize B, Jacques M, and Gottschalk M. Role of capsular sialic acid in virulence and resistance to phagocytosis of Streptococcus suis capsular type 2. FEMS immunology and medical microbiology 14: 195-203, 1996.
11. Chen C, Tang J, Dong W, Wang C, Feng Y, Wang J, Zheng F, Pan X, Liu D, Li M, Song Y, Zhu X, Sun H, Feng T, Guo Z, Ju A, Ge J, Dong Y, Sun W, Jiang Y, Wang J, Yan J, Yang H, Wang X, Gao GF, Yang R, Wang J, and Yu J. A glimpse of streptococcal toxic shock syndrome from comparative genomics of S. suis 2 Chinese isolates. PloS one 2: e315, 2007.
12. Chen S, Xie W, Wu K, Li P, Ren Z, Li L, et al. Suilysin Stimulates the Release of Heparin Binding Protein from Neutrophils and Increases Vascular Permeability in Mice. Front Microbiol. 2016;7:1338.
13. Charland N, Nizet V, Rubens CE, Kim KS, Lacouture S, Gottschalk M. Streptococcus suis serotype 2 interactions with human brain microvascular endothelial cells. Infect Immun. 2000;68:637-43.
14. Cox JC, and Coulter AR. Adjuvants a classification and review of their modes of action. Vaccine 15: 248-256, 1997.
15. Devriese LA, and Haesebrouck F. Streptococcus suis infections in horses and cats. The Veterinary record 130: 380, 1992.
16. De Gregorio E,Caproni E,Ulmer JB. Vaccine adjuvants: mode of action. Frontiers in immunology 4: 214, 2013.
17. De Jong M. Progressive and nonprogressive atrophic rhinitis. Diseases of swine 9: 577-602, 1999.
18. Dominick MA, and Rimler RB. Turbinate atrophy in gnotobiotic pigs intranasally inoculated with protein toxin isolated from type D Pasteurella multocida. American journal of veterinary research 47: 1532-1536, 1986.
19. Du H, Huang W, Xie H, Ye C, Jing H, Ren Z, et al. The genetically modified suilysin, rSLY(P353L), provides a candidate vaccine that suppresses proinflammatory response and reduces fatality following infection with Streptococcus suis. Vaccine. 2013;31:4209-15.
20. Du, H.; Huang, W.; Xie, H.; Ye, C.; Jing, H.; Ren, Z.; Xu, J.The genetically modified suilysin, rSLYP353L, provides a candidate vaccine that suppresses proinflammatory response and reduces fatality following infection with Streptococcus suis. Vaccine 2013, 31, 4209–4215.
21. Du H, Xu L, Wang X, Li X, Ye C, Xu J. [Biological profiles of recombinant Suilysin]. Wei Sheng Wu Xue Bao. 2009;49:792-8.
22. Feng Y, Zhang H, Ma Y, and Gao GF. Uncovering newly emerging variants of Streptococcus suis, an important zoonotic agent. Trends in microbiology 18: 124-131, 2010.
23. Fittipaldi N, Fuller TE, Teel JF, Wilson TL, Wolfram TJ, Lowery DE, and Gottschalk M. Serotype distribution and production of muramidase-released protein, extracellular factor and suilysin by field strains of Streptococcus suis isolated in the United States. Veterinary microbiology 139: 310-317, 2009.
24. Freytag LC, and Clements JD. Bacterial toxins as mucosal adjuvants. Current topics in microbiology and immunology 236: 215-236, 1999.
25. Fukui-Miyazaki A, Ohnishi S, Kamitani S, Abe H, and Horiguchi Y. Bordetella dermonecrotic toxin binds to target cells via the N-terminal 30 amino acids. Microbiology and immunology 55: 154-159, 2011.
26. Ge J, Feng Y, Ji H, Zhang H, Zheng F, Wang C, Yin Z, Pan X, and Tang J. Inactivation of dipeptidyl peptidase IV attenuates the virulence of Streptococcus suis serotype 2 that causes streptococcal toxic shock syndrome. Current microbiology 59: 248-255, 2009.
27. Ghyslaine Vanier, Mariela Segura, Marie-Pier Lecours, Daniel Grenier, Marcelo Gottschalk, Porcine brain microvascular endothelial cell-derived interleukin-8 is firstinduced and then degraded by Streptococcus suis. Microbial Pathogenesis : 46 135-143, 2009.
28. Gupta RK. Aluminum compounds as vaccine adjuvants. Advanced drug delivery reviews 32: 155-172, 1998.
29. Gottschalk MG, Lacouture S, and Dubreuil JD. Characterization of Streptococcus suis capsular type 2 haemolysin. Microbiology 141 ( Pt 1): 189-195, 1995.
30. Gottschalk M, and Segura M. The pathogenesis of the meningitis caused by Streptococcus suis: the unresolved questions. Veterinary microbiology 76: 259-272, 2000.
31. Habjanec L, Halassy B, and Tomasic J. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. International immunopharmacology 8: 717-724, 2008.
32. Hao, H.; Hui, W.; Liu, P.; Lv, Q.; Zeng, X.; jiang, H.; Wang, Y.; Zheng, X.; Zheng, Y.; Li, J.; et al.Effect of Licochalcone A on Growth and Properties of Streptococcus suis. PLoS One 2013, 8, 1–11. 24.
33. Harmon BG, Glisson JR, Latimer KS, Steffens WL, and Nunnally JC. Resistance of Pasteurella multocida A:3,4 to phagocytosis by turkey macrophages and heterophils. American journal of Veterinary Research 52: 1507-1511, 1991.
34. He Z, Pian Y, Ren Z, Bi L, Yuan Y, Zheng Y, et al. Increased production of suilysin contributes to invasive infection of the Streptococcus suis strain 05ZYH33. Mol Med Rep. 2014;10:2819-26.
35. Hildebrand D, Heeg K, and Kubatzky KF. Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent. Infection and immunity 79: 220-228, 2011.
36. Huamao D, Changyun Y,Huaiqi J, Zhihong R, Jianguo X. The genetically modified suilysin, rSLYP353L, provides a candidate vaccine that suppresses proinflammatory response and reduces fatality following infection with Streptococcus suis Vaccine 31:4209–4215, 2013.
37. Holden MT, Hauser H, Sanders M.Rapid evolution of virulence and drug resistance in the emerging zoonotic pathogen Streptococcus suis. PloS one 4: e6072, 2009.
38. Hsueh KJ, Lee JW, Hou SM, Chen HS, Chang TC, and Chu CY. Evaluation on a Streptococcus suis vaccine using recombinant Sao-L protein manufactured by bioreactors as the antigen in pigs. Transboundary and emerging diseases, 2013.( online published )
39. Jacobs AA, Loeffen PL, van den Berg AJ, and Storm PK. Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. Infection and immunity 62: 1742-1748, 1994.
40. Jacobs AA, van den Berg AJ, and Loeffen PL. Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis. The Veterinary record 139: 225-228, 1996.
41. Jang, S. I., H. S. Lillehoj, S. H. Lee and K. W. Lee. Immunoenhancing effects of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection. Veterinary parasitology.172(3-4):221-228, 2010.
42. Jensen FC, Savary JR, Diveley JP, and Chang JC. Adjuvant activity of incomplete Freund's adjuvant. Advanced drug delivery reviews 32: 173-186, 1998.
43. Kataoka Y, Yoshida T, and Sawada T. A 10-year survey of antimicrobial susceptibility of Streptococcus suis isolates from swine in Japan. The Journal of veterinary medical science / the Japanese Society of Veterinary Science 62: 1053-1057, 2000.
44. Kay R. The site of the lesion causing hearing loss in bacterial meningitis: a study of experimental streptococcal meningitis in guinea-pigs. Neuropathology and applied neurobiology 17: 485-493, 1991.
45. King SJ, Heath PJ, Luque I, Tarradas C, Dowson CG, and Whatmore AM. Distribution and genetic diversity of suilysin in Streptococcus suis isolated from different diseases of pigs and characterization of the genetic basis of suilysin absence. Infection and immunity 69: 7572-7582, 2001.
46. Lalonde M, Segura M, Lacouture S, and Gottschalk M. Interactions between Streptococcus suis serotype 2 and different epithelial cell lines. Microbiology 146: 1913-1921, 2000.
47. Lecours MP, Gottschalk M, Houde M, Lemire P, Fittipaldi N, and Segura M. Critical role for Streptococcus suis cell wall modifications and suilysin in resistance to complement-dependent killing by dendritic cells. The Journal of infectious diseases 204: 919-929, 2011.
48. Lee J, and Woo HJ. Antigenicity of partial fragments of recombinant Pasteurella multocida toxin. Journal of microbiology and biotechnology 20: 1756-1763, 2010.
49. Li Y, Martinez G, Gottschalk M, Lacouture S, Willson P, Dubreuil JD, Jacques M, and Harel J. Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs. Infection and immunity 74: 305-312, 2006.
50. Li G, Lu G, Qi Z, Li H, Wang L, Wang Y, et al. Morin Attenuates Streptococcus suis Pathogenicity in Mice by Neutralizing Suilysin Activity. Front Microbiol. 2017;8:460.
51. Liao CM, Huang C, Hsuan SL, Chen ZW, Lee WC, Liu CI, Winton JR, and Chien MS. Immunogenicity and efficacy of three recombinant subunit Pasteurella multocida toxin vaccines against progressive atrophic rhinitis in pigs. Vaccine 24: 27-35, 2006.
52. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145-51.
53. Lun S, Perez-Casal J, Connor W, and Willson PJ. Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2. Microbial pathogenesis 34: 27-37, 2003.
54. Lv Q, Hao H, Bi L, Zheng Y, Zhou X, Jiang Y. Suilysin remodels the cytoskeletons of human brain microvascular endothelial cells by activating RhoA and Rac1 GTPase. Protein Cell. 2014;5:261-4.
55. Madsen LW, Svensmark B, Elvestad K, Aalbaek B, and Jensen HE. Streptococcus suis serotype 2 infection in pigs: new diagnostic and pathogenetic aspects. Journal of comparative pathology 126: 57-65, 2002.
56. Ma,Y. Z., W. H. Fang and C. L. Ke Biological characteristics ofisolates of Streptococcus suis type 2.Chin. J. Vet. Sci. 23: 326-328,2003.
57. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, and Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10: 75-88, 1992.
58. Meng F, Wu NH, Seitz M, Herrler G, Valentin-Weigand P. Efficient suilysin-mediated invasion and apoptosis in porcine respiratory epithelial cells after streptococcal infection under air-liquid interface conditions. Sci Rep. 2016;6:26748.
59. Mai NT, Hoa NT, Nga TV, Linh le D, Chau TT, Sinh DX, et al. Streptococcus suis meningitis in adults in Vietnam. Clin Infect Dis. 2008;46:659-67.
60. Mullan PB, and Lax AJ. Pasteurella multocida toxin stimulates bone resorption by osteoclasts via interaction with osteoblasts. Calcified tissue international 63: 340-345, 1998.
61. Nakai T, Sawata A, Tsuji M, and Kume K. Characterization of dermonecrotic toxin produced by serotype D strains of Pasteurella multocida. American journal of veterinary research 45: 2410-2413, 1984.
62. Orth JH, Blocker D, and Aktories K. His 1025 and His 1223 are essential for the activity of the mitogenic Pasteurella multocida toxin. Biochemistry 42:4971-4977, 2003.
63. Pedersen KB, and Elling F. The pathogenesis of atrophic rhinitis in pigs induced by toxigenic Pasteurella multocida. Journal of comparative pathology 94: 203-214, 1984.
64. Petersen SK. The complete nucleotide sequence of the Pasteurella multocida toxin gene and evidence for a transcriptional repressor, TxaR. Molecular microbiology 4: 821-830, 1990.
65. Ren ZQ, Zheng YL, Gan SZ, Lv QY, Hao HJ, Jiang YQ, et al. [Construction and activities of suilysin mutants]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012;28:580-2.
66. Scalzo AA, Elliott SL, Cox J, Gardner J, Moss DJ, and Suhrbier A. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). Journal of virology 69: 1306-1309, 1995.
67. Segura M, and Gottschalk M. Streptococcus suis interactions with the murine macrophage cell line J774: adhesion and cytotoxicity. Infection and immunity 70: 4312-4322, 2002.
68. Segura M, Gottschalk M, and Olivier M. Encapsulated Streptococcus suis inhibits activation of signaling pathways involved in phagocytosis. Infection and immunity 72: 5322-5330, 2004.
69. Seitz M, Beineke A, Singpiel A, Willenborg J, Dutow P, Goethe R, et al. Role of capsule and suilysin in mucosal infection of complement-deficient mice with Streptococcus suis. Infect Immun. 2014;82:2460-71.
70. Seitz M, Baums CG, Neis C, Benga L, Fulde M, Rohde M, Goethe R, and Valentin-Weigand P. Subcytolytic effects of suilysin on interaction of Streptococcus suis with epithelial cells. Veterinary microbiology 167: 584-591, 2013.
71. Seo J, Pyo H, Lee S, Lee J, and Kim T. Expression of 4 truncated fragments of Pasteurella multocida toxin and their immunogenicity. Canadian journal of veterinary research Revue canadienne de recherche veterinaire 73: 184-189,2009.
72. Staats JJ, Feder I, Okwumabua O, and Chengappa MM. Streptococcus suis: past and present. Veterinary research communications 21: 381-407, 1997.
73. Takeuchi D, Akeda Y, Nakayama T, Kerdsin A, Sano Y, Kanda T, et al. The contribution of suilysin to the pathogenesis of Streptococcus suis meningitis. J Infect Dis. 2014;209:1509-19
74. Tarradas C, Borge C, Arenas A, Maldonado A, Astorga R, Miranda A, et al. Suilysin production by Streptococcus suis strains isolated from diseased and healthy carrier pigs in Spain. Vet Rec. 2001;148:183-4.
75. Vanier G, Segura M, Friedl P, Lacouture S, and Gottschalk M. Invasion of porcine brain microvascular endothelial cells by Streptococcus suis serotype 2. Infection and immunity 72: 1441-1449, 2004.
76. Vanier G, Segura M, Lecours MP, Grenier D, and Gottschalk M. Porcine brain microvascular endothelial cell-derived interleukin-8 is first induced and then degraded by Streptococcus suis. Microbial pathogenesis 46: 135-143, 2009.
77. Wang Q, Chang BJ, Mee BJ, Riley TV. Neuraminidase production by Erysipelothrix rhusiopathiae. Vet Microbiol. 2005;107:265-72.
78. Wijewardana TG, and Sutherland AD. Bactericidal activity in the sera of mice vaccinated with Pasteurella multocida type A. Veterinary Microbiology 39: 924-929, 2001.
79. Willenborg J, Willms D, Bertram R, Goethe R, and Valentin-Weigand P. Characterization of multi-drug tolerant persister cells in Streptococcus suis. BMC microbiology 14: 120, 2014.
80. Wu Z, Li M, Wang C, Li J, Lu N, Zhang R, Jiang Y, Yang R, Liu C, Liao H, Gao GF, Tang J, and Zhu B. Probing genomic diversity and evolution of Streptococcus suisserotype 2 by NimbleGen tiling arrays. BMC genomics 12: 219, 2011.
81. Yan J, Yang H, Wang X, Gao GF, Yang R, and Yu J. A. A glimpse of streptococcal toxic shock syndrome from comparative genomics of S. suis 2 Chinese isolates. PLoS one 2: 315, 2007.
82. Yuste J, Botto M, Paton JC, Holden DW, and Brown JS. Additive inhibition of complement deposition by pneumolysin and PspA facilitates Streptococcus pneumonia septicemia. Journal of immunology 175: 1813-1819, 2005.
83. Zhang S, Wang J, Chen S, Yin J, Pan Z, Liu K, et al. Effects of Suilysin on Streptococcus suis-Induced Platelet Aggregation. Front Cell Infect Microbiol. 2016;6:128.
84. Zhang S, Zheng Y, Chen S, Huang S, Liu K, Lv Q, et al. Suilysin-induced Platelet-Neutrophil Complexes Formation is Triggered by Pore Formation-dependent Calcium Influx. Sci Rep. 2016;6:36787.